ArticleResearch and practice in thrombosis and haemostasis2025
Clinical safety of home treatment for pulmonary embolism: a multicenter registry study of the Asian population.
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The short-term safety of home-based management of pulmonary embolism (PE) in Asian patients remains unclear. Objectives: The aim of the study was to assess the 30-day clinical safety of home-based treatment compared with in-hospital treatment in Japanese patients with PE. Methods: In this multicenter retrospective study, we enrolled consecutive patients diagnosed with acute PE from the Heart and Vascular Disease Outcome Study in Saga and Kyushu Region-venous thromboembolism registry, performed in the Saga prefecture, Japan, between 2015 and 2024. Among the 641 registered patients, 104 and 537 were treated at home and in the hospital, respectively. After performing 1:1 propensity score matching, 208 patients were analyzed. The primary composite outcome was 30-day PE-related death, aggravation of venous thromboembolism, and bleeding events. Bleeding events were defined based on the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries criteria as moderate/severe. Results: After propensity score matching, the mean ± SD patient age was 66 ± 14 years, and 45% of the patients were men. In total, 72% of the patients had deep vein thrombosis, and 81% were treated with a direct oral anticoagulant. The primary composite outcome occurred in 3 patients (3%) in the home treatment group and in 6 patients (6%) in the in-hospital treatment group, with no significant difference between the 2 groups (log-rank test, Conclusion: The risk of PE-related events and bleeding in Japanese patients with PE treated at home was comparable to that of patients who received in-hospital treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.